Trial Profile
Erismodegib in basal cell nevus syndrome patients with basal cell carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Aug 2011
Price :
$35
*
At a glance
- Drugs Sonidegib (Primary)
- Indications Basal cell cancer; Basal cell nevus syndrome
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals Corporation
- 12 Aug 2011 New trial record
- 01 Aug 2011 Results published in the Journal of Investigative Dermatology.